Description

1H-Benzimidazole, 2-[[[4-[(2,2-Dimethyl-1,3-Dioxan-5-Yl)Methoxy]-3,5-Dimethyl-2-Pyridinyl]Methyl]Sulfinyl]-, Sodium Salt (1:1), (+)- is a high-purity, chiral benzimidazole derivative of significant interest in advanced pharmaceutical synthesis. This compound serves as a critical advanced pharmaceutical intermediate (API) for the development of novel therapeutic agents, particularly in the proton pump inhibitor (PPI) class. It is essential for research institutions and pharmaceutical manufacturers engaged in the development of next-generation gastrointestinal treatments and other specialized drug candidates requiring a sophisticated chiral building block.

Application

• Advanced Pharmaceutical Intermediate (API): A key chiral synthon in the research and production of novel proton pump inhibitors (PPIs) and other benzimidazole-based therapeutics.
• Active Pharmaceutical Ingredient (API) Synthesis: Used in the precise chemical synthesis of target drug molecules requiring the (+)-enantiomer of this complex sulfoxide structure.
• Medicinal Chemistry & Drug Discovery: Serves as a valuable scaffold for structure-activity relationship (SAR) studies and the development of new chemical entities in pharmaceutical R&D labs.
• Process Chemistry & Scale-Up: Employed in the optimization and pilot-scale manufacturing of drug candidates prior to commercial production.
• Contract Manufacturing (CMO): Supplied to contract development and manufacturing organizations (CDMOs) for the production of client-specific drug substances.
• Reference Standard: Can be utilized as a high-purity analytical reference standard for quality control and method development in pharmaceutical analysis.

Basic Information

Item	Details
Product Name	1H-Benzimidazole, 2-[[[4-[(2,2-Dimethyl-1,3-Dioxan-5-Yl)Methoxy]-3,5-Dimethyl-2-Pyridinyl]Methyl]Sulfinyl]-, Sodium Salt (1:1), (+)-
CAS No.	913695-00-8
Molecular Formula	C22H27N3O4SNa
Molecular Weight	452.53 g/mol
Synonyms	(+)-Sodium Salt of 2-[[[4-[(2,2-Dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole; Dexlansoprazole Sodium Salt; Dexlansoprazole Related Compound; (R)-(+)-Lansoprazole Sulfone Sodium Salt; TAK-390MR Sodium Salt; (R)-Lansoprazole Sulfoxide Sodium Salt; 1H-Benzimidazole, 2-(((4-((2,2-dimethyl-1,3-dioxan-5-yl)methoxy)-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt, (R)-; Dexlansoprazole Impurity Sodium Salt.
EINECS	Contact for details

Quality Control

Our production of this high-value intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency for critical pharmaceutical applications. Quality is verified through comprehensive analytical testing including HPLC for purity and chiral purity, residual solvent analysis, and identification tests. A detailed Certificate of Analysis (COA) is provided with each batch, documenting compliance with agreed specifications. We support development under cGMP guidelines as required for advanced pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept under dry, inert conditions to maintain stability and purity. For long-term storage, consider desiccated or nitrogen-purged environments.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (HPLC)	≥99.0% (de)
Water Content (KF)	≤2.0%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.